Kyaw Zin Thein
YOU?
Author Swipe
View article: Advances and challenges in immunotherapy in head and neck cancer
Advances and challenges in immunotherapy in head and neck cancer Open
Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy with suboptimal survival outcomes despite advances in surgery, radiotherapy, and chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) t…
View article: Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors
Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors Open
View article: A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab
A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab Open
Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, constituting approximately 13% of all hematologic malignancies. Isatuximab is a monoclona…
View article: Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study Open
View article: Hyperhomocysteinemia-associated Thrombosis in Patients With Pernicious Anemia
Hyperhomocysteinemia-associated Thrombosis in Patients With Pernicious Anemia Open
This rare condition is associated with high incidence of thromboses at unusual sites, multiple-site thromboses, co-existing neuropsychiatric symptoms, high positivity rate for anti-IF antibodies and low recurrent thrombosis rate.
View article: Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions
Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions Open
The ever-expanding development of tissue-agnostic therapies which target malignancies based on specific mutations rather than tissue origin have transformed the landscape of oncology. The purpose of this review is to explore the impact, sa…
View article: 1310 Peripheral blood and tumor gene expression as biomarkers and potential predictors of clinical outcome with HST-1011, an oral CBL-B inhibitor
1310 Peripheral blood and tumor gene expression as biomarkers and potential predictors of clinical outcome with HST-1011, an oral CBL-B inhibitor Open
View article: Histology Agnostic Drug Development: An Updated Review
Histology Agnostic Drug Development: An Updated Review Open
Recent advancements in oncology have led to the development of histology-agnostic therapies, which target genetic alterations irrespective of the tumor’s tissue of origin. This review aimed to provide a comprehensive update on the current …
View article: Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions
Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions Open
NTRK fusions are oncogenic drivers for multiple tumor types. Therefore, the development of selective tropomyosin receptor kinase (TRK) inhibitors, including larotrectinib and entrectinib, has been transformative in the context of clinical …
View article: Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development
Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development Open
The regulatory approvals of tumor-agnostic therapies have led to the re-evaluation of the drug development process. The conventional models of drug development are histology-based. On the other hand, the tumor-agnostic drug development of …
View article: Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug Development
Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug Development Open
The regulatory approvals of tumor agnostic therapies have led to reevaluation of the drug development process. Conventional models of drug development are histology-based. On the other hand, tumor agnostic drug development of a new drug (o…
View article: Cracking the Code of a Rare Colonic Mesentery Gastrointestinal Neuroendocrine Tumor Disguised as Chronic Gastroenteritis: The Critical Art of Timely Detection
Cracking the Code of a Rare Colonic Mesentery Gastrointestinal Neuroendocrine Tumor Disguised as Chronic Gastroenteritis: The Critical Art of Timely Detection Open
Neuroendocrine tumors (NETs) typically present in the setting of metastasis from other solid organs and are considered late manifestations of the disease. Therefore, primary tumors are extremely rare. NETs of the colonic mesentery occur mo…
View article: P1646: A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY
P1646: A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY Open
Topic: 34. Thrombosis and vascular biology - Biology & Translational Research Background: Venous thromboembolism (VTE) is a frequent complication of cancer and cancer treatment. Lymphoma is a highly thrombogenic cancer according to the Kho…
View article: Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy
Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy Open
Advanced gastric cancer is a highly thrombogenic cancer per Khorana score. Recent clinical practice guidelines suggest primary outpatient thromboprophylaxis (POTP) for patients with a Khorana score ≥2. We performed an updated meta-analysis…
View article: Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant
Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant Open
View article: 1625P Cyclin-dependent kinase 4/6 inhibitors (CDKI)-associated venous thromboembolism in patients with hormone receptor (HR)-positive breast cancer
1625P Cyclin-dependent kinase 4/6 inhibitors (CDKI)-associated venous thromboembolism in patients with hormone receptor (HR)-positive breast cancer Open
View article: The contemporary management of cancers of the sinonasal tract in adults
The contemporary management of cancers of the sinonasal tract in adults Open
Sinonasal malignancies make up <5% of all head and neck neoplasms, with an incidence of 0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas significant progress has been made in the management of other cancer…
View article: Identification of <i>KRAS</i><sup><i>G12C</i></sup> Mutations in Circulating Tumor DNA in Patients With Cancer
Identification of <i>KRAS</i><sup><i>G12C</i></sup> Mutations in Circulating Tumor DNA in Patients With Cancer Open
PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRAS G12C mutation has attracted special interest because it is now c…
View article: Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy
Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy Open
Ovarian cancer (OC) is highly associated with venous thromboembolism (VTE). The OC cells stimulate thrombin generation, and chemotherapy potentiates the prothrombotic effect of cancer cells by damaging endothelium and enhancing hypercoagul…
View article: Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study Open
Selinexor is a first-in-class, oral, potent selective inhibitor of exportin-1 (XPO-1), which is overexpressed in various malignancies. Previous phase I and II studies demonstrated the modest activity of the single-agent selinexor in patien…
View article: Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors
Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors Open
View article: Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors Open
View article: Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study Open
View article: Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials Open
Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of random…
View article: Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study Open
View article: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study Open
View article: 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy Open
View article: Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy
Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy Open
Primary ambulatory thromboprophylaxis (PATP) in patients with solid malignancies is not routinely indicated. We performed a meta-analysis of randomized controlled trials (RCTs) to determine the benefit and risk of PATP in patients with non…
View article: Tissue-Agnostic Drug Development: A New Path to Drug Approval
Tissue-Agnostic Drug Development: A New Path to Drug Approval Open
Summary: In recent years, there has been remarkable progress in our understanding of cancer biology, host responses, and the concept of precision oncology. These advances have focused attention on biomarker-driven, tissue-agnostic drug dev…
View article: Precision therapy for RET-altered cancers with RET inhibitors
Precision therapy for RET-altered cancers with RET inhibitors Open